Lexaria Bioscience Announces Positive Blood-Brain-Barrier Results
Lexaria’s technology delivered 195% more nicotine across the blood-brain-barrier conceptually allowing for smaller micro doses in accordance with developing FDA policies. Lexaria’s formulation was 4x faster at reaching its peak…
Lexaria Bioscience Announces Further Advancement of Edibles Nicotine Testing Delivery Measured Within Minutes
Nicotine, in an edible form, delivered to blood plasma within minutes after dosing. Statistically significant positive in vivo results (n=40; two groups of 20 animals). 90.2% greater delivery by the 10-minute mark of the…
Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH™ Powered TurboCBD™ Capsules
Kelowna, British Columbia – August 1, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, is pleased to report significant bioavailability…
Lexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages
Kelowna, British Columbia and Toronto, Ontario – July 31, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP; CSE: LXX; the “Company” or “Lexaria”), a drug delivery platform innovator, and Hill Street…
Lexaria Announces 2018 AGM Results and Corporate Update
Lexaria Announces 2018 AGM Results and Corporate Update Kelowna, British Columbia – July 3, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces the results…
Lexaria Files New Patent Application for Enhancement of Delivery of Lipophilic Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders
Kelowna, British Columbia – June 29, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) a drug delivery platform innovator, announces it has filed an important…
Lexaria Announces Exercises of Existing Warrants and Options
Kelowna, British Columbia – June 19, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces warrant and option transactions. Lexaria announces it has received US$30,000…
Lexaria Bioscience Corp. Structures Nicotine & Pharmaceutical Subsidiaries
Kelowna, British Columbia – May 31, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that, subject to ongoing legal…
Lexaria Bioscience Corp. Receives New Granted Patents
Kelowna, British Columbia – May 23, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces it has received notifications that…
Lexaria Technology Brings “Fast-Acting” to Nuka’s 1906 Cannabis Products with 10-Year Deal Consummating Proof-Of-Concept Relationship
Nuka’s 1906 chocolates, utilizing Lexaria’s DehydraTECH technology, have been recognized for their fast onset times, efficacy, amazing taste and unique formulations Kelowna, British Columbia – April 30, 2018 – Lexaria…